Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced or Metastatic Solid Tumors: early-phase trial registry
5 of 6 indexed Locally Advanced or Metastatic Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 5 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Locally Advanced or Metastatic Solid Tumors: 6 US clinical trials tracked, 5 recruiting.
Locally Advanced or Metastatic Solid Tumors is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Pyrotech Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition locally-advanced-or-metastatic-solid-tumors
OPEN 5 | RECR 83% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)
Locally Advanced or Metastatic Solid Tumors lists 5 open slots (83% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced or Metastatic Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced or Metastatic Solid Tumors is recruiting above its size-band peers.
5 of 6 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Locally Advanced or Metastatic Solid Tumors research.
Pyrotech Therapeutics accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Locally Advanced or Metastatic Solid Tumors enrolment sits around 396 participants.
Median target enrolment is 396 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Locally Advanced or Metastatic Solid Tumors research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma
NCT07066657
Study of XB010 in Subjects With Solid Tumors
Exelixis
NCT06545331
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics
NCT06244992
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co.
NCT06307795
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
NCT04511845
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced or Metastatic Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced or Metastatic Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced or Metastatic Solid Tumors page
6 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Locally Advanced or Metastatic Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pyrotech Therapeutics sponsors the most Locally Advanced or Metastatic Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Pyrotech Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced or Metastatic Solid Tumors condition card totals 6 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.